Pyrhönen S - Search Results

1

Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay.

Rappu P, Nylund C, Ristiniemi N, Kulpakko J, Vihinen P, Hernberg M, Mirtti T, Alanen K, Kallajoki M, Vuoristo MS, Pyrhönen S, Heino J. Rappu P, et al. Among authors: pyrhonen s. Int J Cancer. 2011 May 15;128(10):2382-92. doi: 10.1002/ijc.25571. Int J Cancer. 2011. PMID: 20658534

2

High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.

Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. Nikkola J, et al. Among authors: pyrhonen s. Clin Cancer Res. 2005 Jul 15;11(14):5158-66. doi: 10.1158/1078-0432.CCR-04-2478. Clin Cancer Res. 2005. PMID: 16033831

3

Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival.

Nylund C, Rappu P, Pakula E, Heino A, Laato L, Elo LL, Vihinen P, Pyrhönen S, Owen GR, Larjava H, Kallajoki M, Heino J. Nylund C, et al. Among authors: pyrhonen s. PLoS One. 2012;7(9):e45382. doi: 10.1371/journal.pone.0045382. Epub 2012 Sep 21. PLoS One. 2012. PMID: 23028975 Free PMC article.

4

New prognostic factors and developing therapy of cutaneous melanoma.

Vihinen PP, Pyrhönen SO, Kähäri VM. Vihinen PP, et al. Ann Med. 2003;35(2):66-78. doi: 10.1080/07853890310009980. Ann Med. 2003. PMID: 12795336 Free article. Review.

5

Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.

Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO. Vihinen PP, et al. Acta Oncol. 2007;46(5):678-84. doi: 10.1080/02841860600965020. Acta Oncol. 2007. PMID: 17562445

6

Serum angiogenin levels predict treatment response in patients with stage IV melanoma.

Vihinen P, Kallioinen M, Vuoristo MS, Ivaska J, Syrjänen KJ, Hahka-Kemppinen M, Kellokumpu-Lehtinen PL, Pyrhönen SO. Vihinen P, et al. Clin Exp Metastasis. 2007;24(7):567-74. doi: 10.1007/s10585-007-9093-7. Epub 2007 Aug 29. Clin Exp Metastasis. 2007. PMID: 17762972

7

High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri VM, Pyrhönen S. Nikkola J, et al. Among authors: pyrhonen s. Int J Cancer. 2002 Feb 1;97(4):432-8. doi: 10.1002/ijc.1636. Int J Cancer. 2002. PMID: 11802203 Clinical Trial.

8

Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhönen S. Nikkola J, et al. Among authors: pyrhonen s. Melanoma Res. 2004 Feb;14(1):29-37. doi: 10.1097/00008390-200402000-00005. Melanoma Res. 2004. PMID: 15091191

9

Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma.

Vuoristo M, Vihinen P, Vlaykova T, Nylund C, Heino J, Pyrhönen S. Vuoristo M, et al. Among authors: pyrhonen s. Melanoma Res. 2007 Aug;17(4):215-23. doi: 10.1097/CMR.0b013e328270b935. Melanoma Res. 2007. PMID: 17625451 Clinical Trial.

10

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma.

Vihinen PP, Hernberg M, Vuoristo MS, Tyynelä K, Laukka M, Lundin J, Ivaska J, Pyrhönen S. Vihinen PP, et al. Among authors: pyrhonen s. Melanoma Res. 2010 Aug;20(4):318-25. doi: 10.1097/CMR.0b013e3283390365. Melanoma Res. 2010. PMID: 20375744 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

272 results

Search Page

Filters